ES2181006T3 - Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion. - Google Patents
Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.Info
- Publication number
- ES2181006T3 ES2181006T3 ES97928260T ES97928260T ES2181006T3 ES 2181006 T3 ES2181006 T3 ES 2181006T3 ES 97928260 T ES97928260 T ES 97928260T ES 97928260 T ES97928260 T ES 97928260T ES 2181006 T3 ES2181006 T3 ES 2181006T3
- Authority
- ES
- Spain
- Prior art keywords
- piridil
- immunosuppression
- alcanos
- alkens
- amidas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 PIRIDIL ALKINES Chemical class 0.000 title abstract 4
- 206010062016 Immunosuppression Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- WGNUNYPERJMVRM-UHFFFAOYSA-N 3-pyridylacetic acid Chemical compound OC(=O)CC1=CC=CN=C1 WGNUNYPERJMVRM-UHFFFAOYSA-N 0.000 title 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19624668A DE19624668A1 (de) | 1996-06-20 | 1996-06-20 | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2181006T3 true ES2181006T3 (es) | 2003-02-16 |
Family
ID=7797502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97928260T Expired - Lifetime ES2181006T3 (es) | 1996-06-20 | 1997-06-20 | Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0912176B1 (Direct) |
| JP (1) | JP2000512652A (Direct) |
| AT (1) | ATE224713T1 (Direct) |
| AU (1) | AU3262497A (Direct) |
| DE (2) | DE19624668A1 (Direct) |
| DK (1) | DK0912176T3 (Direct) |
| ES (1) | ES2181006T3 (Direct) |
| PT (1) | PT912176E (Direct) |
| WO (1) | WO1997048397A1 (Direct) |
| ZA (1) | ZA975443B (Direct) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| JPH10338658A (ja) * | 1997-04-08 | 1998-12-22 | Hoechst Marion Roussel Kk | レチノイド作用調節剤 |
| DE19756261A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
| DE19756235A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
| US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
| DE19756212A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19818044A1 (de) * | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| WO2000009132A1 (en) * | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
| EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| DE19908483A1 (de) * | 1999-02-26 | 2000-10-05 | Klinge Co Chem Pharm Fab | Inhibitoren der zellulären Niacinamidmononucleotid-Bildung |
| MXPA03001245A (es) | 2000-08-11 | 2003-05-27 | Wyeth Corp | Metodo para el tratamiento del carcionma positivo para receptores de estrogeno. |
| NZ525056A (en) | 2000-09-29 | 2004-11-26 | Glaxo Group Ltd | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| EP1348434A1 (en) * | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
| GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| BRPI0608436A2 (pt) | 2005-03-17 | 2009-12-29 | Pfizer | derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor |
| PE20071159A1 (es) | 2005-10-31 | 2007-11-30 | Schering Corp | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
| US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| US9006426B2 (en) | 2008-06-24 | 2015-04-14 | Topotarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| RU2011111728A (ru) | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
| EP2453883A1 (en) | 2009-07-17 | 2012-05-23 | Topo Target A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| CN106243023A (zh) | 2010-09-03 | 2016-12-21 | 福马Tm有限责任公司 | 用于抑制nampt的胍化合物和组合物 |
| AR082885A1 (es) | 2010-09-03 | 2013-01-16 | Genentech Inc | Compuestos y composiciones para la inhibicion de nampt |
| RU2617424C2 (ru) | 2010-09-03 | 2017-04-25 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| EP2621903B1 (en) * | 2010-09-29 | 2017-03-01 | Intervet International B.V. | N-heteroaryl compounds |
| BR112013012078A2 (pt) | 2010-11-15 | 2019-09-24 | Abbvie Inc | inibidores de nampt e rock |
| CN103347860A (zh) | 2010-11-15 | 2013-10-09 | Abbvie公司 | Nampt抑制剂 |
| WO2012150952A1 (en) | 2011-05-04 | 2012-11-08 | Forma Tm, Llc | Novel compounds and compositions for the inhibition of nampt |
| MX347459B (es) | 2011-05-09 | 2017-04-26 | Forma Tm Llc | Nuevos compuestos y composiciones para la inhibición de nampt. |
| WO2013170115A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Pyridazine and pyridine derivatives as nampt inhibitors |
| WO2013170113A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Nampt inhibitors |
| CN104271572A (zh) | 2012-05-11 | 2015-01-07 | 艾伯维公司 | 用作nampt抑制剂的噻唑羧酰胺衍生物 |
| HK1208221A1 (en) | 2012-05-11 | 2016-02-26 | Abbvie Inc. | Nampt inhibitors |
| EP2925750A1 (en) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| DK3016946T3 (da) | 2013-07-03 | 2023-01-09 | Karyopharm Therapeutics Inc | Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| AU2016308829A1 (en) | 2015-08-18 | 2018-03-08 | Karyopharm Therapeutics Inc. | (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer |
| US10858347B2 (en) | 2015-12-31 | 2020-12-08 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| WO2018075600A1 (en) | 2016-10-18 | 2018-04-26 | Seattle Genetics, Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| US11931414B2 (en) | 2017-04-27 | 2024-03-19 | Seagen Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| US20200360531A1 (en) | 2018-01-31 | 2020-11-19 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| KR20250107972A (ko) | 2018-05-04 | 2025-07-14 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| US20230023124A1 (en) | 2019-11-06 | 2023-01-26 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| US20240376074A1 (en) | 2021-05-13 | 2024-11-14 | Remedy Plan, Inc. | Nampt inhibitors and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| JP2832979B2 (ja) * | 1988-02-15 | 1998-12-09 | 武田薬品工業株式会社 | 不飽和カルボン酸アミド誘導体 |
| EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
| JPH05506216A (ja) * | 1990-04-10 | 1993-09-16 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 医薬としてのピリジン |
| JPH05506027A (ja) * | 1990-04-10 | 1993-09-02 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 新規ピリジンエステル |
-
1996
- 1996-06-20 DE DE19624668A patent/DE19624668A1/de not_active Ceased
-
1997
- 1997-06-19 ZA ZA9705443A patent/ZA975443B/xx unknown
- 1997-06-20 ES ES97928260T patent/ES2181006T3/es not_active Expired - Lifetime
- 1997-06-20 JP JP10502317A patent/JP2000512652A/ja not_active Withdrawn
- 1997-06-20 AU AU32624/97A patent/AU3262497A/en not_active Abandoned
- 1997-06-20 AT AT97928260T patent/ATE224713T1/de active
- 1997-06-20 WO PCT/EP1997/003244 patent/WO1997048397A1/en not_active Ceased
- 1997-06-20 EP EP97928260A patent/EP0912176B1/en not_active Expired - Lifetime
- 1997-06-20 PT PT97928260T patent/PT912176E/pt unknown
- 1997-06-20 DE DE69715861T patent/DE69715861T2/de not_active Expired - Lifetime
- 1997-06-20 DK DK97928260T patent/DK0912176T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP0912176B1 (en) | 2002-09-25 |
| DK0912176T3 (da) | 2003-01-13 |
| PT912176E (pt) | 2003-01-31 |
| JP2000512652A (ja) | 2000-09-26 |
| ATE224713T1 (de) | 2002-10-15 |
| ZA975443B (en) | 1998-02-10 |
| DE69715861T2 (de) | 2003-06-12 |
| DE69715861D1 (de) | 2002-10-31 |
| WO1997048397A1 (en) | 1997-12-24 |
| DE19624668A1 (de) | 1998-02-19 |
| EP0912176A1 (en) | 1999-05-06 |
| AU3262497A (en) | 1998-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2181006T3 (es) | Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion. | |
| PT923570E (pt) | Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos | |
| DE69731373D1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
| TR199901949T2 (xx) | Lemfositik t�m�rler i�in �areler. | |
| ATE306473T1 (de) | Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide | |
| BR9807734A (pt) | Composto para imunodiagnose de câncer de próstata e métodos para o uso dos memos | |
| DE69434181D1 (de) | Therapeutische Peptid Derivate | |
| ATE263157T1 (de) | Nematizide trifluorbutene | |
| ATE270557T1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
| ES2141128T3 (es) | Combinacion de agentes anti-hormonales y moleculas de fijacion. | |
| BR9805544C1 (pt) | Uso de um composto. | |
| ATE210988T1 (de) | Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen | |
| ATE396205T1 (de) | Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe | |
| BG99177A (bg) | Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза | |
| DK1007537T3 (da) | Receptor-protein med betegnelsen 2F1 | |
| BG100930A (bg) | Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения | |
| NO971341L (no) | Promoter for reseptor tyrosinkinase TIE | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| ES2079068T3 (es) | 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas. | |
| NO983177L (no) | Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft | |
| ATE419861T1 (de) | Peptide mit homing für lymphgefässtumor und ihre verwendung | |
| ATE395935T1 (de) | An der oberfläche von karzinomzellen lokalisiertes colligin/hsp47 | |
| DK0720597T3 (da) | Triarylethylenderivater til terapeutisk anvendelse | |
| DE69807200D1 (de) | Inklusionskomplexe in waessriger loesung | |
| EA200200321A1 (ru) | Апоптин-ассоциированный белок |